SuperworthTarsus Pharmaceuticals price to sales ratio TARS
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- 4.9×
- 3-year median
- 9.3×
- Against its 3-year history
- 6th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 4.7× to 72.5×
- Peer median
- 6.8×
Tarsus Pharmaceuticals' price to sales ratio is 4.9× as of Oct 23, 2026.
That is below its 3-year median of 9.3×, lower than on 94% of days in the last 3 years.
Over that time it ranged from 4.7× in Jul 2026 to 72.5× in Mar 2024.
The median for 10 biotech stocks of a similar size is 6.8×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 4.9× | 4.7× | 9.4× |
| 2025 | 9.5× | 6.8× | 16.4× |
| 2024 | 16.2× | 11.6× | 72.5× |
Against its peers
Companies in Biotechnology nearest Tarsus Pharmaceuticals' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| TARSTarsus Pharmaceuticals | 4.9× |
| ADMAAdma Biologics | 4.7× |
| VCELVericel | 7.1× |
| KRYSKrystal Biotech | 20.9× |
| RGENRepligen | 12.7× |
| MGTXMeiraGTx | 2.2× |
| TECHBIO-TECHNE | 9.4× |
| HALOHalozyme Therapeutics | 8.6× |
| NBIXNeurocrine Biosciences | 4.3× |
| EXELExelixis | 6.6× |
| INCYIncyte | 4.0× |
| Peer median | 6.8× |
Where Tarsus Pharmaceuticals ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Tarsus Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.